Thursday, October 2, 2025 10/2/2025

Novel Designed Multi-Ligands as Tocolytics for Dysregulated Myometrial Pathways in the Treatment of Preterm Labor

Award Number: R21HD112011
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/08/2024
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

Novel Designed Multi-Ligands as Tocolytics for Dysregulated Myometrial Pathways in the Treatment of Preterm Labor - PROJECT SUMMARY ABSTRACT Preterm birth is a major medical problem resulting in disability and death for very preterm infants. Therapeutic approaches to manage preterm labor are off-label and ineffective. No tocolytic therapy in use today is satisfactory beyond 48 hours, and none is FDA approved. Preterm labor more often impacts African American women than their Caucasian counterparts and is exacerbated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which leads to preterm birth in COVID- 19 affected pregnancies. Our central hypotheses are that designed multi-ligand (DML) drugs to be generated in this research that target dysregulated pathways in preterm myometrium will provide a therapeutic benefit in cases of preterm labor while decreasing fetal exposure to the compounds, and that co-administration of the DML’s ‘constituent single entities’ will exhibit synergistic tocolysis. In addition to providing a potential synergistic benefit, we expect that our DMLs will be poorly transported across the placenta due to favorable pharmacokinetic properties of the DMLs, and thus will protect the fetus from exposure. Decreased placental transfer will improve dose-ranging for clinical benefit to prevent preterm labor. This research will justify novel DMLs as potential new tocolytics to prevent preterm birth. This proposal will generate novel DMLs using advanced Medicinal Chemistry techniques and will make extensive use of ex vivo and in vivo experimentation using both human and mouse tissue. The long term goal of this project is to generate first-in-class tocolytics that will delay or halt early labor and prevent preterm birth.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $183,750 )
2025	2025	BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER ED	1664 N VIRGINIA ST # 285	RENO	NV	89557	WASHOE	USA	Child Health and Human Development Extramural Research	000	2	8/19/2025	NON-COMPETING CONTINUATION	$183,750
														Subtotal = $183,750

Issue Date FY: 2024 ( Subtotal = $219,592 )
2024	2024	BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER ED	1664 N VIRGINIA ST # 285	RENO	NV	89557	WASHOE	USA	Child Health and Human Development Extramural Research	000	1	8/8/2024	NEW	$219,592
														Subtotal = $219,592

Grand Total All Awards = $403,342

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel Designed Multi-Ligands as Tocolytics for Dysregulated Myometrial Pathways in the Treatment of Preterm Labor

Award Number: R21HD112011

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/08/2024

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer